Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,918 signal articles · 243 in last 24h · 118,691 total before filter · latest 51m ago
243last 24h
1545last 7d
260● bullish (7d)
159● bearish (7d)
205publishers
AllMacro293Earnings626M&A102Regulatory22Product13Analyst22
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
AvalonBay (AVB): The Best Interest Rate Sensitive Stock to Buy Now
Insider Monkey50d agobullish
AvalonBay (AVB): The Best Interest Rate Sensitive Stock to Buy Now

AvalonBay Communities, Inc. (NYSE:AVB) is one of the 10 Interest Rate Sensitive Stocks to Buy Now. On June 16, 2026, Truist raised its price target on AvalonBay Communities, Inc. (NYSE:AVB) to $202 from $201 and kept a Buy rating. Truist adjusted its model with expectations for 1.3% year-over-year same-store revenue growth in 2026 and 3.9% […]

Axon Soars on Trump Stock Purchase Highlighting Insider Trading Issues
24/7 Wall St.50d agobullish
Axon Soars on Trump Stock Purchase Highlighting Insider Trading Issues

Markets have become increasingly sensitive to any headline that hints at government spending or political influence. Defense contractors, AI companies, and cybersecurity firms can all move sharply on a single news report, even when the underlying information isn’t actually new. That happened again today after CNBC reported that President Trump bought between $1 million and ... Axon Soars on Trump Stock Purchase Highlighting Insider Trading Issues

AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe
Simply Wall St.50d agobullish
AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe

AbbVie (NYSE:ABBV) received positive opinions from the European Medicines Agency's CHMP for RINVOQ in severe alopecia areata and non-segmental vitiligo. If approved, RINVOQ could become the first systemic therapy for non-segmental vitiligo in Europe. The new indications target areas with high unmet medical need in dermatology and immunology. AbbVie has been active across immunology, gastroenterology and virology, and RINVOQ is already a core asset in its portfolio. These fresh CHMP...

AI Didn’t Kill SaaS After All: Why Beaten-Down Software Stocks Are Rebounding
24/7 Wall St.50d agobullish
AI Didn’t Kill SaaS After All: Why Beaten-Down Software Stocks Are Rebounding

The AI investment story has shifted repeatedly over the past year. Investors first piled into semiconductor companies, then power producers, networking firms, and data center infrastructure providers as the race to build AI capacity accelerated. Software companies, however, became the market’s biggest casualty after fears emerged that AI agents could replace many traditional software applications ... AI Didn’t Kill SaaS After All: Why Beaten-Down Software Stocks Are Rebounding

Investing.com50d agobullish
Palantir surges 4% on Nvidia sovereign AI pact as software beats semis

Investing.com -- Palantir Technologies Inc (NASDAQ:PLTR) is trading up 4.6% at $118.09 on Monday, extending a rebound that began Friday when the stock snapped a seven-session losing streak, after the company announced a strategic initiative with NVIDIA Corporation (NASDAQ:NVDA) to deploy open AI models inside classified and air-gapped government environments. The partnership pertains to a jointly developed intelligent engine pairing Nvidia's Blackwell Ultra GPUs and Nemotron open models with Pal